Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
Express News | SELLAS Life Sciences Group Shares Are Trading Higher After the Company Announced the FDA Granted Rare Pediatric Disease Designation to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Sls009 for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS' SLS009 Granted Orphan Drug Designation by EMA for Acute Myeloid Leukemia Treatment
Express News | SELLAS Life Sciences Granted Orphan Drug Designation By European Commission For SLS009, A Novel CDK9 Inhibitor For Treating Acute Myeloid Leukemia
Express News | Sellas Life Sciences Group Inc: On Track to Share Further Data Around Sls009 in Q3 of This Year
Express News | Sellas Receives European Medicines Agency Orphan Drug Designation for Sls009 for the Treatment of Acute Myeloid Leukemia
Express News | SELLAS Life Sciences Granted FDA Rare Pediatric Disease Designation For SLS009 CDK9 Inhibitor For Treatment Of Pediatric Acute Lymphoblastic Leukemia; Eligible For Priority Review Voucher Worth Over $100M Upon Approval
Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
Sellas Falls 17% Amid Phase 3 Study Update for Galinpepimut-S
Express News | Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion by 2029 as Clinical Trials Increase
Express News | SELLAS Life Sciences Announced Review Of Ongoing Phase 3 REGAL Clinical Trial Of Galinpepimut-S In Acute Myeloid Leukemia By IDMC
Express News | Sellas Life Sciences Group Inc - Independent Data Monitoring Committee (Idmc) Recommends Continuation of Phase 3 Regal Trial Without Any Modifications
Express News | Sellas Life Sciences Group Inc: No Safety or Futility Concerns Were Raised Based on Efficacy and Safety Assessment of All Regal Patients
Express News | Sellas Life Sciences Group Inc - Interim Analysis Anticipated by Q4 2024
Express News | Sellas Life Sciences Announces Positive Recommendation From the Independent Data Monitoring Committee of the Phase 3 Regal Trial in Acute Myeloid Leukemia
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4
Express News | Sellas Life Sciences Group- Orr of 33% & 50% Achieved to Date in 60 Mg Qw & 30 Mg Biw Cohorts, Respectively in Phase 2a Trial of Sls009
Express News | Sellas Life Sciences Group Inc - Results Showed That Sls009 Was Well-Tolerated Across All Doses
Express News | Sellas Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of Sls009 in R/R Aml
No Data